HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis

Table 1 Overview of the intended chemotherapy protocol (* patients treated 2009–2013, ** patients treated 2005–2008, i.v. = intravenous, MTX = methotrexate, AraC = cytarabine, i.th. = intrathecal)

	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
Cycle 1–3 (1 cycle = 2 weeks)
- Rituximab 500 mg/m² i.v.*	x
- MTX 3000–5000 mg/m² i.v.		x
- Ifosfamide 800 mg/m² i.v.			x	x	x
- Liposomal AraC 50 mg i.th.**			x
Cycle 4 + 6 (1 cycle = 3 weeks)
- Cytarabine 3000 mg/m² i.v		x	x
- Liposomal AraC 50 mg i.th.**				x
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*				x	x	x
- AraC 10 mg intraventricular (patients < 65 ys)*							x
Cycle 5 (1 cycle = 2 weeks)
- MTX 3000–5000 mg/m² i.v.		x
- Ifosfamide i.v. 800 mg/m² i.v.			x	x	x
- Liposomal AraC 50 mg i.th.**			x
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)*			x	x	x
- AraC10 mg intraventricular (patients < 65 ys)*						x
Cycle 5 was repeated for patients < 65 ys